Clinical trials: Oxycontin
Healthy
Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers
To estimate the effect of food on the pharmacokinetics and relative bioavailability of oxycodone following oral administration of single 40 mg doses of PF 00345439 Formulation K taken whole or after chewing in healthy volunteers.
- Trial name
- NCT02117583
- Testing
- Oxycodone
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Pain Therapeutics
Healthy
Fed Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets
The objective of this open-label, randomized, two-period, crossover study was to evaluate the oral bioavailability of the Mallinckrodt controlled-release test tablet formulation of oxycodone 40 mg compared to an equivalent oral…
- Trial name
- NCT00853268
- Testing
- Controlled-Release Oxycodone Hydrochloride 40 mg, OxyContin® 40 mg tablet
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Mallinckrodt
Postoperative Pain, Acute
PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)
The goal of this clinical trial is to evaluate the analgesic activity of PF614 (an oral oxycodone prodrug extended-release analgesic) for control of postsurgical pain in subjects scheduled for abdominoplasty surgery.
- Trial name
- NCT06602271
- Testing
- PF614 capsule
- Where
- 3 sites in United States
- Volunteers
- 320 people
- Sponsor
- Ensysce Biosciences
Respiratory Depression
Single Dose Crossover Study to Compare the Respiratory Drive After Administration of Belbuca, Oxycodone and Placebo.
The purpose of this study is to explore and compare VRH after administration of Belbuca, Oxycodone HCl and Placebo in recreational opioid users.
- Trial name
- NCT03996694
- Testing
- Belbuca 300 µg, Belbuca 600 µg, Belbuca 900 µg
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- BioDelivery Sciences International
Healthy
To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (40 mg) relative to the original OxyContin® (OXY) formulation (40 mg) in the fasted state.
- Trial name
- NCT01101165
- Testing
- Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl)
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP
Thoracic Surgery, Pneumonectomy
Personalized Postoperative Pain Management Following Thoracic Surgery in Adults
The proposed research is an important extension of an ongoing perioperative personalized analgesia and intravenous opioid pharmacogenetic research.
- Conditions
- Thoracic Surgery, Pneumonectomy, Lobectomy, Segmentectomy
- Trial name
- NCT05525923
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- OpalGenix, Inc
Malignant Pain, Non-malignant Pain
To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain
This study is aimed to demonstrate equivalence between combinations of lower strength OXN PR tablets (OXN PR LST) and single higher strength OXN PR tablets (OXN PR HST) taken at the same overall daily dose.
- Trial name
- NCT02321397
- Testing
- Oxycodone, Naloxone
- Where
- Germany
- Volunteers
- 155 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Low Back Pain
Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain
The primary objective is to assess the efficacy of oxycodone/naloxone (OXN) for the management of opioid-induced constipation (OIC) compared to oxycodone controlled-release tablets (OXY) in subjects with moderate to severe low…
- Trial name
- NCT01427270
- Testing
- Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release
- Where
- 194 sites in United States, Czechia and 2 more
- Volunteers
- 455 people
- Sponsor
- Purdue Pharma LP
Chronic Pain
OTR Tablet 40 mg Fed-state Bioequivalence Study
An open-label, single dose, randomized, cross-over study to confirm the bioequivalence (BE) of OTR tablet 40 mg and OXYCONTIN tablet 40 mg in a fed state in Chinese subjects with chronic pain.
- Trial name
- NCT03398330
- Testing
- Oxycodone Tamper Resistant, OxyContin®
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Healthy
Fasting Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets
The objective of this open-label, randomized, two-period, crossover study was to evaluate the oral bioavailability of the Mallinckrodt controlled-release test tablet formulation of oxycodone 40 mg compared to an equivalent oral…
- Trial name
- NCT00853892
- Testing
- Controlled-Release Oxycodone Hydrochloride 40 mg tablet, OxyContin® 40 mg tablet
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Mallinckrodt
Osteoarthritis, Back Pain
A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis
The purpose of this study is to compare oxycodone/naloxone combination tablet and codeine/paracetamol tablets in the treatment of moderate to severe chronic low back pain or pain due to osteoarthritis.
- Trial name
- NCT00784810
- Testing
- Oxycodone/Naloxone, Codeine/Paracetamol
- Where
- United Kingdom
- Volunteers
- 247 people
- Sponsor
- Napp Pharmaceuticals Limited
Management of Moderate to Severe Pain
Pharmacokinetics Study of ALO-02 and OxyContin
To characterize the single- and multiple-dose pharmacokinetics of oxycodone following the administration of ALO-02 40 Mg Twice Daily, ALO-02 80 Mg Once Daily or Oxycontin 40 Mg Twice Daily in Healthy Volunteers
- Trial name
- NCT01557257
- Testing
- ALO-02, Naltrexone block, OxyContin
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pain
Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids
The purpose of this study is to characterize the safety of oxycodone hydrochloride (HCl) controlled-release (CR) tablets in opioid tolerant pediatric patients aged 6 to 16 years, inclusive, with moderate to severe malignant…
- Trial name
- NCT01192295
- Testing
- Oxycodone HCl controlled-release tablets
- Where
- 47 sites in United States, Greece and 6 more
- Volunteers
- 155 people
- Sponsor
- Purdue Pharma LP
Joint Diseases, Arthritis
A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease
The purpose of this study is to compare bowel function/constipation that occurs during tapentadol treatment with that occuring during oxycodone treatment, as measured by the frequency of spontaneous bowel movements per week.
- Conditions
- Joint Diseases, Arthritis, Osteoarthritis
- Trial name
- NCT00784277
- Testing
- oxycodone CR, oxycodone IR, Tapentadol ER (CG5503)
- Volunteers
- 597 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy Volunteers
A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (10 mg) relative to the original OxyContin® (OXY) formulation (10 mg) in the fasted state.
- Trial name
- NCT01100086
- Testing
- Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl)
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP
Pain
Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain
The main objective of the study is to evaluate the patient preference for pain treatment with respect to quality of life in patients with moderate to severe non malignant pain.
- Trial name
- NCT01167699
- Testing
- Oxycodone and naloxone
- Where
- Belgium
- Volunteers
- 174 people
- Sponsor
- Mundipharma Pharmaceuticals B.V.
Substance Abuse Detection
Risk of Shopping Behavior of Tapentadol Immediate-Release (IR) Compared to Oxycodone Immediate-Release (IR)
The purpose of this study is to compare the risk of shopping behavior of tapentadol immediate release with the risk of shopping behavior of oxycodone immediate release.
- Trial name
- NCT01545778
- Testing
- Tapentadol IR, Oxycodone IR
- Volunteers
- 646,620 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Pain
Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain
Evaluate the efficacy of treatment with Fentanyl Buccal Tablets (FBT) compared with immediate release oxycodone in alleviating breakthrough pain in opioid tolerant patients with chronic pain.
- Trial name
- NCT00463047
- Testing
- Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone
- Where
- 45 sites in United States
- Volunteers
- 323 people
- Sponsor
- Cephalon
Pain
Long-term Safety of PF-00345439 (Oxycodone)
Long-Term Safety Of PF-00345439 (Oxycodone) In Patients With Moderate To Severe Chronic Low Back Pain Or Osteoarthritis
- Trial name
- NCT01559701
- Testing
- PF-00345439
- Volunteers
- 823 people
- Sponsor
- Pain Therapeutics
Cancer
Immediate-Release Oxycodone Capsules Study in Cancer Pain
The efficacy of dose titration of OxyNorm™(Oxycodone) immediate-release capsules versus morphine immediate-release tablets in the treatment of cancer pain.
- Trial name
- NCT01675622
- Testing
- Oxycodone, Morphine
- Volunteers
- 242 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd